Capricor soars on potential FDA review extension, filing amendments

Capricor Therapeutics is working with the FDA to potentially extend the review deadline for its Duchenne muscular dystrophy therapy deramiocel by submitting new open-label extension data and amendments, prompting a 68% surge in the company's stock.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.